XML 29 R9.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Millions
9 Months Ended
Sep. 26, 2020
Sep. 28, 2019
Cash Flows From (For) Operating Activities    
Net income (loss) $ 12.4 $ 165.1
Adjustments to derive cash flows:    
Depreciation and amortization 284.7 293.5
Loss (Gain) on sale of business 18.6 (72.4)
Share-based compensation 43.9 40.9
Impairment charges 202.4 42.9
Change in financial assets (25.9) (18.5)
Loss on extinguishment of debt 20.0 0.2
Restructuring charges 1.9 26.7
Deferred income taxes 25.7 10.1
Amortization of debt premium (1.7) (3.8)
Other non-cash adjustments, net (12.0) 38.3
Subtotal 570.0 523.0
Increase (decrease) in cash due to:    
Accounts receivable 106.4 (12.1)
Inventories (93.2) (78.3)
Prepaid expenses (23.8) (4.7)
Accounts payable 15.2 33.7
Payroll and related taxes (2.2) (10.6)
Accrued customer programs (35.5) (82.7)
Accrued liabilities (16.0) (24.8)
Accrued income taxes (9.0) (65.8)
Other, net 13.9 20.6
Subtotal (44.2) (224.7)
Net cash from (for) operating activities 525.8 298.3
Cash Flows From (For) Investing Activities    
Proceeds from royalty rights 3.2 2.2
Purchase of equity method investment (15.0) 0.0
Acquisitions of businesses, net of cash acquired (106.0) (749.5)
Proceeds from the Royalty Pharma contingent milestone 0.0 250.0
Asset acquisitions (34.1) (86.2)
Additions to property, plant and equipment (104.3) (90.3)
Net proceeds from sale of business 187.8 183.4
Other investing, net 8.1 0.6
Net cash from (for) investing activities (60.3) (489.8)
Cash Flows From (For) Financing Activities    
Issuances of long-term debt 743.8 600.0
Payments on long-term debt (590.0) (476.0)
Borrowings (repayments) of revolving credit agreements and other financing, net 0.1 0.8
Deferred financing fees (6.7) (1.0)
Premiums on early debt retirement (19.0) 0.0
Issuance of ordinary shares 0.0 0.7
Cash dividends (93.0) (83.6)
Other financing, net (14.9) (7.6)
Net cash from (for) financing activities 20.3 33.3
Effect of exchange rate changes on cash and cash equivalents 9.3 5.6
Net increase (decrease) in cash and cash equivalents 495.1 (152.6)
Cash and cash equivalents, beginning of period 354.3 551.1
Cash and cash equivalents, end of period $ 849.4 $ 398.5